368 related articles for article (PubMed ID: 16804803)
1. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
4. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
6. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
McQuirter M; Castiglia LL; Loiselle CG; Wong N
Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
[TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
8. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
[TBL] [Abstract][Full Text] [Related]
9. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
10. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.
Metcalfe KA; Esplen MJ; Goel V; Narod SA
Psychooncology; 2004 Jan; 13(1):14-25. PubMed ID: 14745742
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
van Roosmalen MS; Stalmeier PF; Verhoef LC; Hoekstra-Weebers JE; Oosterwijk JC; Hoogerbrugge N; Moog U; van Daal WA
J Clin Oncol; 2004 Aug; 22(16):3293-301. PubMed ID: 15310772
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
13. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
14. Predictors of and satisfaction with bilateral prophylactic mastectomy.
Stefanek ME; Helzlsouer KJ; Wilcox PM; Houn F
Prev Med; 1995 Jul; 24(4):412-9. PubMed ID: 7479633
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic mastectomy and genetic testing: an update.
Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction.
Swisher EM; Babb S; Whelan A; Mutch DG; Rader JS
J Reprod Med; 2001 Feb; 46(2):87-94. PubMed ID: 11255821
[TBL] [Abstract][Full Text] [Related]
17. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
18. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
20. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
